Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy

American Journal of Respiratory and Critical Care Medicine

Volumn 182, Issue 9, 2010, Pages 1171-1177

  Ghofrani, Hossein Ardeschir ^a   Morrell, Nicholas W ^b   Hoeper, Marius M ^c   Olschewski, Horst ^d   Peacock, Andrew J ^e   Barst, Robyn J ^f   Shapiro, Shelley ^g   Golpon, Heiko ^c   Toshner, Mark ^b   Grimminger, Friedrich ^a   Pascoe, Steve ^h  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b PAPWORTH HOSPITAL   (United Kingdom)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Exercise; Hemodynamics; Imatinib; Pulmonary hypertension

Indexed keywords

IMATINIB; PLACEBO;

ANOREXIA; ARTERY RUPTURE; ARTICLE; CATHETER COMPLICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HEART ARREST; HEART LEFT VENTRICLE FAILURE; HEART OUTPUT; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMIC PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HEMOPTYSIS; HUMAN; LIVER DYSFUNCTION; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PANCREATITIS; PERIPHERAL EDEMA; PRESYNCOPE; PRIORITY JOURNAL; PRURITUS; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SYNCOPE; TREATMENT OUTCOME; TREATMENT RESPONSE; VERTIGO;

ADULT; DOUBLE-BLIND METHOD; EXERCISE TEST; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INTENTION TO TREAT ANALYSIS; LUNG; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 77956709644     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201001-0123OC     Document Type: Article

References (33)

1. Badesch DB, Champion HC, Gomez Sanchez MA, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeige R, Olschewski H, Oudiz RJ, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:55S-66S.
2. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-349.
3. Barst R, Gibbs JSR, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galiè N. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:78S-84S.
4. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894-2903.
5. Ghofrani HA, Wilkins MW, Rich S. Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. Circulation 2008;118:1195-1201.
6. Macchia A, Marchioli R, Marfisi R, Scarano M, Levantesi G, Tavazzi L, Tognoni G. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 2007;153:1037-1047. (Pubitemid 46809838)
7. Galiè N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:394-403.
8. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, Stenmark KR, Thistlethwaite PA, Weissmann N, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:20S-31S.
9. Balasubramaniam V, Tang JR, Maxey A, Plopper CG, Abman SH. Mild hypoxia impairs alveolarization in the endothelial nitric oxide synthase-deficient mouse. Am J Physiol Lung Cell Mol Physiol 2003;284:L964-L971. (Pubitemid 36687131)
10. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79:1283-1316. (Pubitemid 29473317)
11. Humbert M, Monti G, Fartoukh M, Magnan A, Brenot F, Rain B, Capron F, Galanaud P, Duroux P, Simonneau G, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998;11:554-559. (Pubitemid 28194842)
12. Balasubramaniam V, Le Cras TD, Ivy DD, Grover TR, Kinsella JP, Abman SH. Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 2003;284:L826-L833. (Pubitemid 36459029)
13. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811-2821. (Pubitemid 41434408)
14. Young KC, Torres E, Hehre D, Suguihara C, Hare J. Neonatal c-kit mutant mice exhibit decreased susceptibility to hypoxia-induced pulmonary hypertension. Circulation 2009;120:S750-S751.
15. Day E, Waters B, Spiegel K, Alnadaf T, Manley PW, Buchdunger E, Walker C, Jarai G. Inhibition of collagen induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 2008;599:44-53.
16. de Kogel CE, Schellens JH. Imatinib. Oncologist 2007;12:1390-1394.
17. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005;353:1412-1413. (Pubitemid 41362714)
18. Patterson KC, Weissmann A, Ahmadi T, Farber HW. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006;145:152-153. (Pubitemid 46780594)
19. Souza R, Sitbon O, Parent F, Simonneau G, Humbert M. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 2006;61:736. (Pubitemid 44211786)
20. Barst RJ, Ghofrani A, Morrell N, Hoeper M, Olschewski H, Peacock A, Shapiro S, Pascoe S, Quinn DA. Imatinib mesylate treatment for severe pulmonary arterial hypertension: a proposed phase III 24-week double-blind placebo-controlled randomized clinical trial [abstract]. Chest Meeting Abstracts 2009;136:64S.
21. Ghofrani HA, Morrel NW, Hoeper MM, Olschewski H, Peacock D, Barst RJ, Shapiro S, Golpon H, Toshner M, Grimminger F, et al. Imatinib in patients with severe pulmonary artery hypertension (PAH) refractory to standard therapy [abstract]. Am J Respir Crit Care Med 2009;179:A1044.
22. Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock A, Barst RJ, Shapiro S, Quinn DA, Pascoe S. Long term use of imatinib in patients with severe pulmonary arterial hypertension [abstract]. Am J Respir Crit Care Med 2010;181:A2513.
23. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-117.
24. Rubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. (Pubitemid 34984638)
25. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, et al., for The Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
26. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, et al. Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-2157.
27. Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, et al., PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149:521-530.
28. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257-1263.
29. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-916.
30. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370:2011-2019.
31. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, et al. IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.
32. Hatfield A, Owen S, Pilot PR. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med 2007;13:13, author reply 15-16.
33. Quintás-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007;6:834-848.